Animal Health Archives
Animal Pharmaceuticals
10/20/2026
Commercial Readiness Starts with an Audit-Ready Supply Chain
The animal health industry is evolving rapidly. Biologics, vaccines, reproductive technologies, regenerative medicine applications, and other advanced therapies are reaching important commercial milestones and expanding into broader distribution networks. As organizations move beyond clinical development and pilot programs, they often discover that commercialization requires more than increased production capacity. It demands a supply chain capable of delivering consistency, traceability, and compliance at scale.
Managing the Cold Chain
10/20/2026
Extended Manufacturability: Why Cryopreservation is a Commercial Enabler
For cell therapy developers approaching commercialization, manufacturing architecture is a strategic consideration. Decisions made early in the development phases regarding starting material sourcing, process design, storage strategy, and supply chain architecture begin to influence capacity planning, cost structures, operational flexibility, and ultimately patient access.
Articles
08/18/2026
Beyond Clinical Success: Bianca Gustafson on Building Supply Chains That Scale
In a recent Contract Pharma interview, Bianca Gustafson, Senior Director of Program Management at Cryoport Systems, shared an important perspective on the transition from clinical development to commercialization. According to Gustafson, a common mistake organizations make is assuming that commercial readiness is an extension of clinical operations, when actually commercialization requires a full-on shift in how supply chains are designed and scaled.
Articles
05/26/2026
Cryoport Systems in Labiotech on Where CGT Supply Chains Start to Break
As more cell and gene therapy programs push toward later-stage trials and commercialization, a familiar set of pressures is starting to surface. What once felt manageable at smaller scale begins to take more effort to hold together as volumes pick up. A recent article in Labiotech, developed in collaboration with Cryoport Systems, looks closely at where that strain comes from and how it often traces back to decisions made much earlier in development.
Articles
05/26/2026
Cryoport Systems with ISCT on Why Early-Phase Development is Starting to Strain
As advanced therapy programs move faster toward first-in-human (FIH), the pressure isn’t just showing up at commercial scale. It’s appearing much earlier than many teams expect. A recent article Cryoport Systems published with ISCT takes a closer look at that shift, highlighting why execution (not feasibility) is increasingly becoming the constraint in early development.
Industry Insights
03/19/2026
ATC 2026 Panel Recap: Harnessing Technological Innovation to Optimize Supply Chain and Logistics in Advanced Therapies
Advanced Therapies Congress 2026 hosted a panel discussion, Harnessing Technological Innovation to Optimize Supply Chain and Logistics in Advanced Therapies, that centered on a reality the field continues to confront... while the desire for digital acceleration is strong, the industry’s underlying infrastructure is not yet positioned to fully benefit from it. Alison Pritchard, VP Business Development, joined fellow panelists to examine where technology can make a meaningful impact today and where foundational alignment must come first.
Managing the Cold Chain
02/26/2026
Building Investor Confidence Through an Intentional Supply Chain Strategy
In early investment conversations, scientific innovation used to carry most of the weight. A compelling mechanism of action, a clear unmet need, and solid early data together were enough to advance the discussion and give investors a sense of potential. In today’s funding environment, however, that has shifted. Today, investors quickly move past the science and begin investigating whether a program can operate with the discipline and scalability required to grow.
Managing the Cold Chain
07/28/2025
Turning Risk into Resilience with Supply Chain Resilience for CDMOs
Contract Development and Manufacturing Organizations (CDMOs) are under more pressure than ever to deliver reliable results in an unpredictable world. From geopolitical instability to material shortages to increasingly complex regulatory expectations, the risks facing clinical and commercial programs have intensified. For CDMOs, these risks don’t just affect their own operations, they directly impact their clients’ ability to bring therapies to patients.
Managing the Cold Chain
05/29/2025